Securities code: Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) securities abbreviation: Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Announcement No.: 2022018 Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd
Announcement of resolutions of the fourth meeting of the Fourth Board of supervisors
The board of supervisors and all supervisors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal liabilities for the authenticity, accuracy and integrity of its contents according to law.
1、 Meetings of the board of supervisors
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. (hereinafter referred to as "the company") issued the notice of the fourth meeting of the Fourth Board of supervisors on March 17, 2022 by telephone, e-mail, personal delivery, etc. The meeting was held by means of communication on March 28, 2022. The meeting was presided over by Ms. Cao Hong, chairman of the board of supervisors. The convening and convening procedures, the qualifications of participants and the procedures for discussion and voting of the meeting comply with the relevant provisions of the company law of the people's Republic of China and the articles of association of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) pharmaceutical (Shanghai) Co., Ltd.
2、 Deliberation at the meeting of the board of supervisors
After careful deliberation and voting by the supervisors attending the meeting, the following resolutions were adopted:
(I) the proposal on the company's work report of the board of supervisors in 2021 was deliberated and adopted. The voting results: 3 in favor, 0 against and 0 abstention.
This proposal shall be submitted to the general meeting of shareholders of the company for deliberation.
(II) deliberated and passed the proposal on the company's financial final accounts report in 2021
Voting results: 3 in favor, 0 against and 0 abstention.
This proposal shall be submitted to the general meeting of shareholders of the company for deliberation.
(III) voting status of the proposal on the company's financial budget report for 2022: 3 in favor, 0 against and 0 abstention.
This proposal shall be submitted to the general meeting of shareholders of the company for deliberation.
(IV) the proposal on the company's annual profit distribution plan for 2021 was deliberated and passed. Audited by Ernst & Young Huaming Certified Public Accountants (special general partnership), the net profit attributable to the shareholders of the listed company in 2021 was 1805851156 yuan (consolidated statement), and the net profit of the parent company was 5693317114 yuan. In 2021, no cash dividends, bonus shares, capital stock will be transferred from accumulation fund, and undistributed profits will be carried forward to the next year.
For details, please refer to the website of Shanghai Stock Exchange on the same day (www.sse. Com. CN.) And the announcement on the company's annual profit distribution plan in 2021 (Announcement No.: 2022019) of the designated media.
Voting results: 3 in favor, 0 against and 0 abstention.
This proposal shall be submitted to the general meeting of shareholders of the company for deliberation.
(V) the proposal on the company's 2021 annual report and summary was reviewed and approved. After review, the board of supervisors considered that the preparation and review procedures of the company's 2021 annual report were in line with relevant laws and regulations, the articles of association and other internal rules and regulations; The content and format of the company's 2021 annual report comply with relevant regulations and fairly reflect the company's financial status and operating results in 2021; During the preparation of the annual report, it is not found that the personnel of the company participating in the preparation and deliberation of the annual report have violated the confidentiality provisions; All members of the board of supervisors guarantee that the information disclosed in the 2021 annual report of the company is true, accurate and complete without any false records, misleading statements or major omissions, and bear legal liabilities for the authenticity, accuracy and integrity of its contents in accordance with the law.
For details, please refer to the website of Shanghai Stock Exchange on the same day (www.sse. Com. CN.) And the 2021 annual report of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. and the 2021 annual report summary of Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. of the designated media.
Voting: 3 in favor, 0 against and 0 abstention.
This proposal shall be submitted to the general meeting of shareholders of the company for deliberation.
(VI) the proposal on the renewal of the company's 2022 audit institution was deliberated and adopted. Ernst & Young Huaming Certified Public Accountants (special general partnership) followed the independent auditing standards for Chinese certified public accountants, diligently and impartially expressed audit opinions, reflecting good professional norms and ethics. In accordance with the requirements of the company law and other laws, regulations and relevant provisions, the board of supervisors agreed to appoint Ernst & Young Huaming Certified Public Accountants (special general partnership) as the audit institution of the company in 2022. For details, please refer to the website of Shanghai Stock Exchange on the same day (www.sse. Com. CN.) And the announcement on renewing the appointment of accounting firms (Announcement No.: 2022021) of the designated media.
Voting: 3 in favor, 0 against and 0 abstention.
This proposal shall be submitted to the general meeting of shareholders of the company for deliberation.
(VII) deliberated and passed the proposal on the remuneration of supervisors of the company in 2022
Voting results: 3 in favor, 0 against and 0 abstention.
This proposal shall be submitted to the general meeting of shareholders of the company for deliberation.
(VIII) deliberated and approved the special report on the deposit and actual use of the company's raised funds in 2021
For details, please refer to the website of Shanghai Stock Exchange (www.sse. Com. CN.) published by the company on the same day And the special report on the deposit and actual use of the company's raised funds in 2021 (Announcement No.: 2022020).
Voting results: 3 in favor, 0 against and 0 abstention.
(IX) deliberation and approval of the company's annual report on environmental and social governance
For details, please refer to the website of Shanghai Stock Exchange on the same day (www.sse. Com. CN.) The company's 2021 environmental, social and corporate governance report. Voting results: 3 in favor, 0 against and 0 abstention.
It is hereby announced.
Sunshine Guojian Pharmaceutical(Shanghai) Co.Ltd(688336) Pharmaceutical (Shanghai) Co., Ltd. board of supervisors March 29, 2022
